International Journal For Multidisciplinary Research

E-ISSN: 2582-2160     Impact Factor: 9.24

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 6 Issue 3 May-June 2024 Submit your research before last 3 days of June to publish your research paper in the issue of May-June.

Secukinumab: A Breakthrough in the Treatment of Autoimmune Disease

Author(s) V.P.Kuzhali
Country India
Abstract Secukinumab is a significant advancement in the treatment of autoimmune disease, particularly psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. By targeting interleukin-17A(IL-17A), it offers a focused approach to mitigating inflammation. This article provides a comprehensive overview of Secukinumab, exploring its mechanism of action, clinical efficacy, safety profile, administration, and ongoing research aimed at expanding its therapeutic scope.
Keywords Secukinumab, autoimmune disease, IL-17A, psoriasis, psoriatic arthritis, ankylosing spondylitis, biologic therapy
Field Medical / Pharmacy
Published In Volume 6, Issue 3, May-June 2024
Published On 2024-05-11
Cite This Secukinumab: A Breakthrough in the Treatment of Autoimmune Disease - V.P.Kuzhali - IJFMR Volume 6, Issue 3, May-June 2024. DOI 10.36948/ijfmr.2024.v06i03.20102
DOI https://doi.org/10.36948/ijfmr.2024.v06i03.20102
Short DOI https://doi.org/gttvc6

Share this